KRAS Proto-Oncogene, GTPase Peptide 1

CPTC-KRAS4B-5

KRAS Proto-Oncogene, GTPase Peptide 1

IgG

Rabbit Monoclonal Antibody

02/06/2024

Recombinant Full-length

00532

KRAS Proto-Oncogene, GTPase Peptide 1

CPTC-KRAS4B Peptide 1

KRAS Proto-Oncogene, GTPase; KRAS1; KRAS2; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; Kirsten Rat Sarcoma Viral Oncogene Homolog; GTPase KRas; C-Ki-Ras; K-Ras4B; K-Ras 2; RASK2; V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog; Kirsten Rat Sarcoma Viral Proto-Oncogene; Cellular Transforming Proto-Oncogene; Cellular C-Ki-Ras2 Proto-Oncogene; Transforming Protein P21; PR310 C-K-Ras Oncogene; C-Kirsten-Ras Protein; Proto-Oncogene GTPase; K-Ras P21 Protein; Oncogene KRAS2; EC 3.6.5.2; C-Ki-Ras2; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; C-K-Ras; KI-RAS; Ki-Ras; K-Ras; CFC2; RALD; NS3; OES; NS

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.KRAS (KRAS Proto-Oncogene, GTPase) is a Protein Coding gene. Diseases associated with KRAS include Oculoectodermal Syndrome and Schimmelpenning-Feuerstein-Mims Syndrome. Among its related pathways are Envelope proteins and their potential roles in EDMD physiopathology and MET promotes cell motility. Gene Ontology (GO) annotations related to this gene include GTP binding and protein-containing complex binding. An important paralog of this gene is HRAS.Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306).

12p12.1

NP_004976.2

P01116

N/A

Synthetic Peptide

N/A

2310

07/06/2022